JP5588967B2 - Pharmaceutical composition container - Google Patents

Description

  The present invention relates to a pharmaceutical composition container, and more particularly, to a pharmaceutical composition container that can enhance cleanliness when swallowing the pharmaceutical composition.

  Patent Document 1 discloses a multi-chamber container. This multi-chamber container partitions a plurality of spaces so as to communicate with each other. These spaces are closed in a state where they can communicate with each other by a force applied from the outside. In any of these spaces, the granular agent is accommodated in a sealed state. The other space contains a dense fluid substance in a sealed state. Each space is communicated with each other, and after the granular material and the concentrated fluid substance are collected and mixed, the mixture can be taken out from a take-out port provided in any one of the spaces.

  According to the container disclosed in Patent Document 1, it is possible to take the granular agent by an extremely simple operation. Moreover, according to the multi-chamber container disclosed in Patent Document 1, the patient's resistance to taking can be greatly reduced.

Japanese Patent Laid-Open No. 10-234820

  However, in the invention disclosed in Patent Document 1, there is a problem that when taking a granule, there is a very high possibility that bacteria or other substances that adversely affect the patient enter the patient's body.

  The technical problem of the present invention has been made to solve the above-mentioned problems, and an object of the present invention is to provide a pharmaceutical composition container that can enhance cleanliness when swallowing the pharmaceutical composition. It is in.

  The pharmaceutical composition container of the present invention will be described with reference to the drawings. Note that the use of the reference numerals in the figure in this column is intended to assist understanding of the contents of the invention, and is not intended to limit the contents to the illustrated range.

  In order to achieve the above object, according to one aspect of the present invention, the pharmaceutical composition container 10 includes at least three spaces 30, 32, 34, 36, 38 in the container body 20. The pharmaceutical composition container 10 further includes a cover 22. Between two adjacent spaces 140, 142, 144, and 146 are closed. The space 140, 142, 144, 146 between two adjacent spaces opens when a force is applied from the outside of the pharmaceutical composition container 10. At least one of the spaces is an open space 38 having an opening 60. A swallowing aid substance 40 is accommodated in a swallowing aid substance chamber 30 which is at least one of the spaces. The pharmaceutical compositions 80 and 82 are accommodated in the pharmaceutical composition chambers 34 and 36 which are at least one of the spaces. A portion of the container body 20 that forms the open space 38 is covered by the cover 22.

  Between two adjacent spaces 140, 142, 144, and 146 are closed. When force is applied to it from the outside of the pharmaceutical composition container 10, it opens. By opening there, it becomes possible to guide the swallowing auxiliary substance 40 from the swallowing auxiliary substance chamber 30 to the pharmaceutical composition chambers 34 and 36. When the swallowing auxiliary substance 40 is guided to the pharmaceutical composition chambers 34 and 36, the pharmaceutical compositions 80 and 82 are mixed with the swallowing auxiliary substance 40. Accordingly, when the opening 60 is applied to the mouth of the person and the swallowing auxiliary substance 40 and the pharmaceutical compositions 80 and 82 are pushed out of the opening 60, the mixture of the pharmaceutical composition 80 and 82 and the swallowing auxiliary substance 40 becomes the person's mouth. It goes into the mouth and is swallowed. By the way, the part which forms the space 38 with an opening among the container main bodies 20 is covered with the cover 22 before the part is applied to a person's mouth. Thereby, the cleanliness of the part is kept high. As a result, cleanliness when swallowing the pharmaceutical composition can be enhanced.

The cover 22 which is above mentioned is, Ru der integrally with the container body 20.

At least three spaces to above mentioned 30, 32 and the cover 22 that is lined to form a single column. In this case, a space 38 with openings is arranged at one end of the row. A cover 22 is disposed at the other end of the row. The container body 20 and the cover 22 can be bent, and the container body 20 and the cover 22 are bent, so that the opening 60 and the cover 22 are opposed to each other.

  Moreover, it is desirable that the inclusions 42 and 44 are accommodated in the pharmaceutical composition chambers 34 and 36 described above. In this case, at least the surface of the inclusions 42 and 44 is dissolved with respect to the component of the swallowing auxiliary substance 40. The inclusions 42 and 44 contain pharmaceutical compositions 80 and 82.

  When the swallowing auxiliary substance 40 is guided to the pharmaceutical composition chambers 34 and 36, at least the surface of the inclusions 42 and 44 is dissolved with respect to the components of the swallowing auxiliary substance 40. Accordingly, when the opening 60 is placed on the mouth of a person who has difficulty in swallowing and the swallowing auxiliary substance 40 and the inclusions 42 and 44 are pushed out from the opening 60, the person who has difficulty in swallowing while being wrapped in the swallowing auxiliary substance 40 The contents 42 and 44 are placed in the mouth. At this time, the surfaces of the inclusions 42 and 44 are melted. Since the surface is melted after being wrapped in the swallowing auxiliary substance 40, even if it is difficult for swallowing, the contents 42 and 44 can be swallowed easily. By swallowing the inclusions 42 and 44, the pharmaceutical compositions 80 and 82 are also swallowed. However, the pharmaceutical compositions 80 and 82 in the inclusions 42 and 44 are not scattered until the inclusions 42 and 44 are sufficiently melted. Furthermore, the residual amount of the pharmaceutical compositions 80 and 82 in the pharmaceutical composition chambers 34 and 36 can be reduced by wrapping the pharmaceutical compositions 80 and 82 with the inclusions 42 and 44.

According to another aspect of the present invention, the pharmaceutical composition container 351 includes a plurality of spaces 370, 372, and 374 in the container body. The container body is provided with an opening formation scheduled portion 394 where the opening is scheduled to be formed. When a force is applied from the outside of the pharmaceutical composition container 351, the opening opens the opening formation scheduled portion 394, thereby allowing the outside of the pharmaceutical composition container 351 to communicate with the space. Between two adjacent spaces 370, 372, and 374, 390 and 392 are closed. When a force is applied from the outside of the pharmaceutical composition container 351, the space 390, 392 between two adjacent spaces 370, 372, 374 opens. The swallowing assistance substance 40 is accommodated in the swallowing assistance substance chamber 370 that is at least one of the spaces. The pharmaceutical composition is accommodated in the pharmaceutical composition chambers 372 and 374 which are at least one of the spaces. The container body can be bent. The pharmaceutical composition container 351 further includes a cover 378. The cover 378 is disposed adjacent to the container body. The cover 378 is integrated with the container body. The cover 378 can insert and remove the portion 354 provided with the opening formation scheduled portion 394 in the container main body. A plurality of spaces 370, 372, 374 and a cover 378 are arranged so as to form one row. A portion 354 of the container body where the opening formation scheduled portion 394 is provided is disposed at one end of the row. A cover 378 is disposed at the other end of the row. The cover 378 can be bent. Since the container body and the cover 378 are bent, the portion 354 provided with the opening formation scheduled portion is covered with the cover 378.

  ADVANTAGE OF THE INVENTION According to this invention, the cleanliness at the time of swallowing a pharmaceutical composition can be improved.

It is a partially broken view of the pharmaceutical composition container according to the first embodiment of the present invention. It is sectional drawing of the pharmaceutical composition container concerning 1st Embodiment of this invention. It is an expanded sectional view of the pharmaceutical composition container concerning a 1st embodiment of the present invention. It is a figure which shows the manufacture procedure of the pharmaceutical composition container concerning 1st Embodiment of this invention. It is a figure which shows the usage method of the pharmaceutical composition container concerning 1st Embodiment of this invention. It is a partially broken figure of the pharmaceutical composition container concerning 2nd Embodiment of this invention. It is a partially broken figure of the pharmaceutical composition container concerning the reference form of this invention. It is a partially broken figure of the pharmaceutical composition container concerning 3rd Embodiment of this invention. It is a partially broken figure of the pharmaceutical composition container concerning 4th Embodiment of this invention. It is a partially broken figure of the pharmaceutical composition container concerning 5th Embodiment of this invention. It is an external view of the pharmaceutical composition container concerning 5th Embodiment of this invention. It is a figure which shows the condition where the cover insertion part is inserted in the cover concerning 5th Embodiment of this invention, and the root has come out of the cover. It is a rear view of the situation where the cover insertion part is inserted in the cover concerning a 5th embodiment of the present invention. It is a partially broken figure of the pharmaceutical composition container concerning 6th Embodiment of this invention. It is a figure which shows the condition which is bending the pharmaceutical composition container concerning 6th Embodiment of this invention. It is a figure which shows the condition after one end is inserted in the cover in the pharmaceutical composition container concerning 6th Embodiment of this invention. It is a partially broken figure of the pharmaceutical composition container concerning 7th Embodiment of this invention. It is a partially broken figure which shows the one end part in manufacture of the pharmaceutical composition container concerning 7th Embodiment of this invention. It is a perspective view which shows the one end part in manufacture of the pharmaceutical composition container concerning 7th Embodiment of this invention. It is a partially broken figure of the pharmaceutical composition container concerning 8th Embodiment of this invention. It is an external view of the condition where the end is inserted in the cover in the pharmaceutical composition container concerning 8th Embodiment of this invention.

  Hereinafter, embodiments of the present invention will be described with reference to the drawings. In the following description, the same parts are denoted by the same reference numerals. Their names and functions are also the same. Therefore, detailed description thereof will not be repeated.

<First embodiment>
Hereinafter, the pharmaceutical composition container 10 according to the first embodiment of the present invention will be described.

  The configuration of the pharmaceutical composition container 10 according to the present embodiment will be described with reference to FIG. The pharmaceutical composition container 10 according to the present embodiment includes a container body 20 and a cover 22 integrated with the container body 20. The container body 20 and the cover 22 according to the present embodiment are formed by bonding two laminated materials 50 together. The laminated material 50 will be described later.

  The container body 20 includes a swallowing auxiliary substance chamber 30, an intermediate chamber 32, a first pharmaceutical composition chamber 34, a second pharmaceutical composition chamber 36, and a space 38 with an opening. The swallowing auxiliary substance chamber 30, the intermediate chamber 32, the first pharmaceutical composition chamber 34, and the second pharmaceutical composition chamber 36 are formed so as to maintain airtightness with respect to the external space around the pharmaceutical composition container 10. Yes.

  The cover 22, the swallowing auxiliary substance chamber 30, the intermediate chamber 32, the first pharmaceutical composition chamber 34, the second pharmaceutical composition chamber 36, and the open space 38 are arranged so as to form one row. As is apparent from FIG. 1, a space 38 with openings is disposed at one end of the row. A cover 22 is disposed at the other end of the row. FIG. 2 is a cross-sectional view of the pharmaceutical composition container 10 according to the present embodiment. In the form as shown in FIG. 2, the cover 22 can cover the outside of the portion of the container body 20 that forms the open space 38. This is possible because the laminated material 50 according to the present embodiment can be bent.

  With reference to FIG. 1 again, the items accommodated in the swallowing auxiliary substance chamber 30, the first pharmaceutical composition chamber 34, and the second pharmaceutical composition chamber 36 will be described.

  A swallowing auxiliary substance 40 is accommodated in the swallowing auxiliary substance chamber 30. The swallowing auxiliary substance 40 in the present embodiment is a sterilized jelly containing water. In the present embodiment, the moisture content of the jelly is set so as to satisfy the following requirements. The requirement is that at least the time from when the swallowing auxiliary substance 40 covers the surfaces of the first and second inclusions 42 and 44, which will be described later, until the first and second inclusions 42 and 44 are completely dissolved. This is a requirement that 2 minutes can be secured.

  In the first pharmaceutical composition chamber 34, a first inclusion 42 is accommodated. In the first inclusion 42, a granular medicine or other first pharmaceutical composition 80 is contained. The material of the first inclusion 42 according to this embodiment is a starch wafer having a thickness of 15 μm.

  A second inclusion 44 is accommodated in the second pharmaceutical composition chamber 36. A second pharmaceutical composition 82 is stored in the second storage 44. The second pharmaceutical composition 82 is a substance different in kind from the granular first pharmaceutical composition 80. The material of the second inclusion 44 according to this embodiment is a starch wafer having a thickness of 10 μm. In addition, the opening of the 1st thing 42 and the 2nd thing 44 is sealed by twisting the part which corresponds to the inlet_port | entrance of the 1st pharmaceutical composition 80 or the 2nd pharmaceutical composition 82. FIG.

  The reason why the oblate is used as the material of the first and second items 42 and 44 is that the functions described below are required for the first and second items 42 and 44. The function is a function that when the swallowing auxiliary substance 40 covers the surface of the first inclusion 42 or the second inclusion 44, the surfaces start to melt, and after they are swallowed, they completely dissolve. The oblate used for the first inclusion 42 is thicker than the oblate used for the second inclusion 44, so that the time from the start of covering by the swallowing auxiliary substance 40 until it completely melts is longer than that of the second inclusion 44. This is necessary. This is necessary because the first inclusion 42 is covered with the swallowing auxiliary substance 40 earlier than the second inclusion 44. The reason why the 10 μm thick wafer is used as the material of the second inclusion 44 is to secure at least 2 minutes from when it is covered with the swallowing aid 40 until it completely melts. Of course, the thickness of the wafer should be appropriately selected according to the material.

  The swallowing auxiliary substance chamber 30, the first pharmaceutical composition room 34, and the second pharmaceutical composition room 36 do not affect the first pharmaceutical composition 80, the second pharmaceutical composition 82, and the swallowing auxiliary substance 40. Gas (for example, nitrogen gas) is sealed as necessary.

  Incidentally, the intermediate chamber 32 and the open space 38 in this embodiment are vacant until the first weak seal 140 to the fourth weak seal 146 described later are peeled off. An empty room is a space in which nothing is accommodated or a gas that does not affect the first pharmaceutical composition 80, the second pharmaceutical composition 82, or the swallowing auxiliary substance 40 is accommodated. The open space 38 has an opening 60. The opening 60 allows the outside of the swallowing auxiliary substance chamber 30, the intermediate chamber 32, the first pharmaceutical composition chamber 34, the second pharmaceutical composition chamber 36, and the open space 38 to communicate with the inside thereof. However, until all of the first weak seal 140 to the fourth weak seal 146 are peeled off, the opening 60 has the swallowing auxiliary substance chamber 30, the intermediate chamber 32, the first pharmaceutical composition chamber 34, and the second pharmaceutical composition chamber 36. Among these, the inside of what communicates with the space 38 with an opening is communicated with the outside of those spaces.

  The swallowing auxiliary substance chamber 30 and the intermediate chamber 32 are partitioned by a first weak seal 140. The intermediate chamber 32 and the first pharmaceutical composition chamber 34 are partitioned by a second weak seal 142. The first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36 are partitioned by a third weak seal 144. A space between the second pharmaceutical composition chamber 36 and the open space 38 is partitioned by a fourth weak seal 146. The first weak seal 140, the second weak seal 142, the third weak seal 144, and the fourth weak seal 146 (these are collectively referred to as “first weak seal 140 to fourth weak seal 146”) are the container body 20. It is arrange | positioned in the part which hits between two adjacent things among the space with which is equipped.

  The strength of the first weak seal 140 to the fourth weak seal 146 is lower than the strength of the bottom strong seal 160 and the strength of the side strong seal 162. The bottom strong seal 160 is a portion where the surfaces of the laminated material 50 are bonded to each other at the boundary between the container body 20 and the cover 22. The side strong seal 162 is a portion excluding the first weak seal 140 to the fourth weak seal 146 and the bottom strong seal 160 in the portion where the surfaces of the laminated material 50 are bonded to each other. In the case of the present embodiment, the strength of the first weak seal 140 to the fourth weak seal 146 is the pressure of the swallowing auxiliary substance 40 (this pressure is due to the fact that an adult applied force from outside the swallowing auxiliary substance chamber 30). ) That can be destroyed by In addition, between the swallowing auxiliary substance chamber 30 and the intermediate chamber 32, between the intermediate chamber 32 and the first pharmaceutical composition chamber 34, between the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36, and The specific method for breaking the space between the second pharmaceutical composition chamber 36 and the open space 38 is not limited to the method of breaking by the pressure of the swallowing auxiliary substance 40. For example, the first weak seal 140 to the fourth weak seal 146 may be torn by pinching and pulling the two laminated materials 50 with both hands.

  FIG. 3 is an enlarged cross-sectional view of the pharmaceutical composition container 10 according to the present embodiment. The configuration of the laminated material 50 and the configurations of the first weak seal 140 to the fourth weak seal 146 will be described with reference to FIGS. 1 and 3. The laminated material 50 according to the present embodiment includes an outer skin material 100, an intermediate material 102, and a closing material 104 (Note that these three-layer structures of the laminated material 50 are not shown in FIG. 2 and are omitted. Have been). The closing materials 104, 104 of the two laminated materials 50 are fused to each other. This fused portion is destroyed prior to the skin material 100 and the intermediate material 102 by the force applied from the outside of the pharmaceutical composition container 10. Compared to the melting point of the skin member 100 and the melting point of the intermediate member 102, the melting point of the closing member 104 is low. Therefore, when heat is applied to the laminated material 50 from the outside of the skin material 100, the closing material 104 is melted before the skin material 100 and the intermediate material 102 are melted. Since the closing material 104 is melted before the outer skin material 100 and the intermediate material 102 are melted, only the closing material 104 can be fused. This fused portion is the first weak seal 140 to the fourth weak seal 146. Only the fourth weak seal 146 is shown in FIG.

  The material of the closing material 104 corresponding to the first weak seal 140 to the fourth weak seal 146 is different from the material of the closing material 104 corresponding to the bottom strong seal 160 and the side strong seal 162 (however, the material of the outer skin material 100 or The material of the intermediate member 102 is the same between the portion corresponding to the first weak seal 140 to the fourth weak seal 146 and the portion corresponding to the bottom strong seal 160 and the side strong seal 162). Since they are different, the strength of the first weak seal 140 to the fourth weak seal 146 can be made lower than the strength of the bottom strong seal 160 and the strength of the side strong seal 162. Incidentally, in the present embodiment, the material of the outer skin material 100 is polyethylene terephthalate. The material of the intermediate material 102 is nylon. The material of the part corresponding to the 1st weak seal 140 thru | or the 4th weak seal 146 among the obstruction | occlusion materials 104 is polyethylene.

  FIG. 4 is a diagram illustrating a manufacturing procedure of the pharmaceutical composition container 10 according to the present embodiment. The manufacturing procedure of the pharmaceutical composition container 10 will be described with reference to FIG. The first step is a step of superimposing the two laminated materials 50 and 50 and heating the portion corresponding to the side portion of the pharmaceutical composition container 10. Thereby, as shown in FIG. 4A, the side strong seal 162 is formed. The second step is a step of heating the vicinity of the intermediate chamber 32 in the laminated material 50. As a result, as shown in FIG. 4B, a first weak seal 140 and a second weak seal 142 are formed. A 3rd step is a step which inserts the 1st inclusion 42 between the two laminated materials 50 and 50, as FIG.4 (C) shows. The fourth step is a step of heating the vicinity of the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36 in the laminated material 50. Thereby, the 3rd weak seal | sticker 144 is formed as FIG.4 (D) shows. The fifth step is a step of inserting the second inclusion 44 between the two laminated materials 50 and 50 as shown in FIG. 4 (E). The sixth step is a step of heating the area between the second pharmaceutical composition chamber 36 and the open space 38 in the laminated material 50. Thereby, as shown in FIG. 4F, a fourth weak seal 146 is formed. The seventh step is a step of filling the swallowing auxiliary substance 40 between the two laminated materials 50. At this time, first, the portion of the first weak seal 140 in the container body 20 is bent, and the swallowing auxiliary substance chamber 30 is directed upward. When the swallowing auxiliary substance chamber 30 faces upward, a nozzle (not shown) is inserted into the swallowing auxiliary substance chamber 30 and the swallowing auxiliary substance 40 is filled. The eighth step is a step of heating the boundary portion between the container body 20 and the cover 22. As a result, the bottom strong seal 160 is formed as shown in FIG. In the ninth step, as shown in FIG. 4 (H), after the boundary portion between the container body 20 and the cover 22 is bent, the portion of the container body 20 that forms the open space 38 is formed between the cover 22. It is a step to insert into. The pharmaceutical composition container 10 completed through these steps is stored in a paper box (not shown) and distributed.

  FIG. 5 is a diagram illustrating a method of using the pharmaceutical composition container 10 according to the present embodiment. The procedure for taking out the first pharmaceutical composition 80 and the second pharmaceutical composition 82 from the pharmaceutical composition container 10 and taking them will be described with reference to FIG.

  First, a caregiver or the like pulls out the distal end portion of the container main body 20 from the cover 22 so that the pharmaceutical composition container 10 in the form shown in FIG. 4 (H) is shown in FIG. 1 or FIG. 4 (G). In the form shown in Next, a caregiver or the like pushes the swallowing auxiliary substance chamber 30 from the outside of the pharmaceutical composition container 10 and peels the first weak seal 140 by the pressure from the inside of the swallowing auxiliary substance chamber 30. When the first weak seal 140 is peeled off, the swallowing auxiliary substance 40 is pushed out to the intermediate chamber 32. The pushed swallowing auxiliary substance 40 fills the intermediate chamber 32.

  In this state, when a caregiver or the like continues to push the swallowing auxiliary substance chamber 30 from the outside of the pharmaceutical composition container 10, the second weak seal 142 is peeled off by the pressure of the swallowing auxiliary substance 40 inside the intermediate chamber 32. At this time, the cover 22 is folded toward the container body 20. When the second weak seal 142 is peeled off, the swallowing auxiliary substance 40 is pushed out into the first pharmaceutical composition chamber 34. The pushed swallowing aid substance 40 fills the first pharmaceutical composition chamber 34. From this time, the surface of the first inclusion 42 starts to melt by the swallowing auxiliary substance 40.

  After the swallowing auxiliary substance 40 is pushed out into the first pharmaceutical composition chamber 34, a caregiver or the like causes the patient 200 to hold the pharmaceutical composition container 10. When the pharmaceutical composition container 10 is prepared, the patient 200 further folds the cover 22 folded toward the container body 20 toward the container body 20, and squeezes the container body 20 and the cover 22. Thereby, pressure is applied to the swallowing auxiliary substance 40. As a result of the pressure applied to the swallowing assisting substance 40, the third weak seal 144 is peeled off. When the third weak seal 144 is peeled off, the swallowing auxiliary substance 40 together with the first inclusion 42 is pushed out into the second pharmaceutical composition chamber 36. The pushed swallowing auxiliary substance 40 fills the second pharmaceutical composition chamber 36. From this time, the surface of the second inclusion 44 also starts to melt by the swallowing auxiliary substance 40.

  After the swallowing auxiliary substance 40 is pushed out into the second pharmaceutical composition chamber 36, the patient 200 further folds the container body 20 and the cover 22 in the direction from the swallowing auxiliary substance chamber 30 toward the second pharmaceutical composition chamber 36, And squeeze them further. Thereby, pressure is applied to the swallowing auxiliary substance 40. As a result of the pressure applied to the swallowing aid 40, the fourth weak seal 146 is peeled off. When the fourth weak seal 146 is peeled off, the swallowing assisting substance 40, the first storage object 42, and the second storage object 44 are pushed out into the space 38 with the opening. They are swallowed through the open space 38 and the patient's 200 mouth. At this time, since the surfaces of the first and second items 42 and 44 are dissolved in the swallowing auxiliary substance 40, the surfaces of the first and second items 42 and 44 are easy to slip. Since the surface of the 1st thing 42 and the 2nd thing 44 becomes easy to slip, the 1st thing 42 and the 2nd thing 44 are swallowed smoothly.

  As described above, the pharmaceutical composition container 10 according to the present embodiment has the following eight effects. The first effect is that the first pharmaceutical composition 80 and the second pharmaceutical composition 82 can be swallowed easily. A 2nd effect is an effect that the bitterness is suppressed when the 1st pharmaceutical composition 80 and the 2nd pharmaceutical composition 82 have a bitter taste. The third effect is an effect that the first pharmaceutical composition 80 and the second pharmaceutical composition 82 can be prevented from scattering in the mouth. The fourth effect is that there is no need to worry about the stability of the first pharmaceutical composition 80 and the second pharmaceutical composition 82. The fifth effect is an effect that various kinds of solids can be taken by a person who has difficulty in swallowing. The sixth effect is that the cleanliness when taking the first pharmaceutical composition 80 and the second pharmaceutical composition 82 can be improved. The seventh effect is that the first and second items 42 and 44 can be pushed out smoothly. The eighth effect is that the residual amount of the pharmaceutical composition 80, 82 inside the pharmaceutical composition container 10 can be reduced (in the case of this embodiment, the residual amount can be made an amount close to zero). It is.

  The first effect will be described in detail. The first storage 42 and the second storage 44 enter the mouth of the patient 200 while being wrapped in the swallowing assistance substance 40. At this time, the surfaces of the first inclusion 42 and the second inclusion 44 are melted. Since the surface is melted while being wrapped in the swallowing aid 40, even the patient 200 who is difficult to swallow can easily swallow the first and second items 42 and 44. Since the first stored product 42 and the second stored product 44 contain the pharmaceutical composition 80, swallowing the first stored product 42 and the second stored product 44 allows the first stored pharmaceutical product 80 and the second stored pharmaceutical composition 44. The object 82 is also swallowed. Thereby, the 1st pharmaceutical composition 80 and the 2nd pharmaceutical composition 82 can be swallowed easily.

  The second effect will be described in detail. As described above, the first collection 42 and the second collection 44 enter the mouth of the patient 200 while being wrapped in the swallowing auxiliary substance 40. As a result, the first pharmaceutical composition 80 and the second pharmaceutical composition 82 which are the contents of the first collection 42 and the second collection 44 are the swallowing auxiliary substance 40, the first collection 42 and the second collection 44. Will be double wrapped. Since the first pharmaceutical composition 80 and the second pharmaceutical composition 82 are doubly wrapped, even if the first pharmaceutical composition 80 and the second pharmaceutical composition 82 are drugs, the tongue of the patient 200 has a bitter taste. The possibility of feeling is reduced. As a result, the bitterness of the drug is suppressed.

  The third effect will be described in detail. As described above, the first pharmaceutical composition 80 and the second pharmaceutical composition 82 are double-wrapped by the swallowing auxiliary substance 40, the first inclusion 42 and the second inclusion 44. Thereby, possibility that the 1st pharmaceutical composition 80 and the 2nd pharmaceutical composition 82 will scatter in the mouth of the patient 200 becomes low. As a result, scattering of the first pharmaceutical composition 80 and the second pharmaceutical composition 82 in the mouth can be suppressed.

  The fourth effect will be described in detail. The first pharmaceutical composition 80 and the second pharmaceutical composition 82 are chemical substances. When chemical substances come into contact, chemical reactions often occur. Due to the chemical reaction, the pharmaceutical composition loses its action as a medicine. For this reason, in many cases, a plurality of pharmaceutical compositions cannot be stored in a mixed state. When storing them in a mixed state, it is necessary to check beforehand whether their effects are lost. The pharmaceutical composition container 10 according to the present embodiment is provided with a plurality of spaces. It is substantially the same to store a single pharmaceutical composition in each space and to store a plurality of pharmaceutical compositions separately. This is the reason why it is not necessary to worry about the stability of the pharmaceutical composition if the pharmaceutical composition container 10 according to the present embodiment is used. Since there is no need to worry about the stability of the pharmaceutical composition, there is no need to examine in advance whether the efficacy of a plurality of pharmaceutical compositions has been lost.

  The fifth effect will be described. After sequentially inducing the swallowing auxiliary substance 40 into the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36, swallowing the swallowing auxiliary substance 40, the first inclusion 42 and the second inclusion 44, The activity of the first pharmaceutical composition 80 and the second pharmaceutical composition 82 itself does not have much influence on the difficulty of swallowing. Thereby, various kinds of solids can be taken for those who have difficulty in swallowing.

  The sixth effect will be described. Prior to use of the pharmaceutical composition container 10, a portion of the container body 20 that forms the open space 38 is covered with the cover 22. Thereby, the frequency with which bacteria etc. adhere to the part which forms the space 38 with an opening among the container main bodies 20 becomes low. In particular, compared to the case where the opening of the container body 20 that touches the mouth is formed, the frequency of attachment of bacteria or the like is lower. When an opening is formed by destroying a portion of the container body 20 that touches the mouth, it is necessary to touch that portion with an instrument or hand when destroying that portion. This is because bacteria and viruses attached to these instruments and hands may adhere to the parts. In the case of the pharmaceutical composition container 10 according to this embodiment, the first weak seal 140 to the fourth weak seal 146 can be swallowed so that the swallowing auxiliary substance 40, the first inclusion 42, and the second inclusion 44 can be swallowed. Since it is not necessary to touch the portion of the container body 20 that touches the mouth with an instrument or hand, the possibility of attachment of bacteria or viruses can be reduced. As a result, cleanliness when taking the first pharmaceutical composition 80 and the second pharmaceutical composition 82 can be improved.

  The seventh effect will be described. The end portion of the first pharmaceutical composition chamber 34 on the second pharmaceutical composition chamber 36 side becomes narrower as it approaches the second pharmaceutical composition chamber 36, and the first encapsulating is contained in the first pharmaceutical composition chamber 34. Since the object 42 is accommodated, when the 1st inclusion 42 is pushed out by the swallowing assistance substance 40, it can implement smoothly. The end of the second pharmaceutical composition chamber 36 on the side of the open space 38 is narrowed as it approaches the open space 38, and the second inclusion 44 is accommodated in the second pharmaceutical composition chamber 36. Therefore, the second inclusion 44 is also pushed out with the same smoothness.

  The eighth effect will be described. When the swallowing auxiliary substance 40 and the first and second inclusions 42 and 44 are pushed out from the opening 60, the first pharmaceutical composition 80 and the second pharmaceutical composition 82 therein are also pushed out at the same time. As a result, the remaining amounts of the first pharmaceutical composition 80 and the second pharmaceutical composition 82 in the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36 are set to the first and second inclusions 42 and 44, respectively. Compared to the case where the first pharmaceutical composition 80 and the second pharmaceutical composition 82 are not contained in the container. Moreover, the first and second items 42 and 44 according to this embodiment are sealed. Since it is sealed, the possibility that the first pharmaceutical composition 80 and the second pharmaceutical composition 82 leak out of the first and second inclusions 42 and 44 is extremely low. Since the possibility is very low, the residual amount of the first pharmaceutical composition 80 and the second pharmaceutical composition 82 inside the pharmaceutical composition container 10 is reduced (actually, the residual amount is made an amount close to zero). be able to.

<Second Embodiment>
Hereinafter, the pharmaceutical composition container 210 according to the second embodiment of the present invention will be described. In addition, the same code | symbol is attached | subjected to the same thing as what was demonstrated in 1st Embodiment. In the present embodiment, detailed description thereof will not be repeated.

  FIG. 6 is a partially cutaway view of the pharmaceutical composition container 210 according to the present embodiment. The configuration of the pharmaceutical composition container 210 according to this embodiment will be described with reference to FIG. The pharmaceutical composition container 210 according to this embodiment includes a container body 220 and a cover 222. The container body 220 is formed of a single laminated material 50 that is folded and has an outer peripheral portion bonded thereto. The cover 222 is formed of the laminated material 50 like the container body 220. The cover 222 is integrated with the container main body 220. In FIG. 6, the hatching at the left end of the pharmaceutical composition container 210 indicates a cross section of the laminated material 50.

  The container body 220 has a swallowing auxiliary substance chamber 230, a pharmaceutical composition chamber 232, and a space 234 with an opening. The swallowing auxiliary substance chamber 230 and the pharmaceutical composition chamber 232 are formed so as to maintain airtightness with respect to the external space around the pharmaceutical composition container 210.

  In the swallowing auxiliary substance chamber 230, the swallowing auxiliary substance 40 is accommodated. The first composition 42 is accommodated in the pharmaceutical composition chamber 232. A first pharmaceutical composition 80 is stored in the first stored product 42. Until the first weak seal 240 and the second weak seal 242 described later are peeled off, the open space 234 is an empty space.

  In addition, in the swallowing auxiliary substance chamber 230 and the pharmaceutical composition room 232, a gas that does not affect the first pharmaceutical composition 80 and the swallowing auxiliary substance 40 is sealed as necessary.

  The swallowing auxiliary substance chamber 230 and the pharmaceutical composition chamber 232 are partitioned by a first weak seal 240. The pharmaceutical composition chamber 232 and the open space 234 are partitioned by a second weak seal 242. The 1st weak seal 240 and the 2nd weak seal 242 will be arrange | positioned in the part which hits between two adjacent things among the spaces formed by the container main body 220. FIG.

  The strength of the first weak seal 240 and the second weak seal 242 is lower than the strength of the bottom strong seal 260 and the strength of the side strong seal 262. The bottom strong seal 260 is a portion where the surfaces of the laminated material 50 are bonded to each other at the boundary between the container main body 220 and the cover 222. The side strong seal 262 is a portion excluding the first weak seal 240 and the second weak seal 242 and the bottom strong seal 260 in the portion where the surfaces of the laminated material 50 are bonded to each other. In the case of the present embodiment, the strength of the first weak seal 240 and the second weak seal 242 is a strength that can be broken by the pressure of the swallowing auxiliary substance 40, as in the first embodiment. Note that, as in the first embodiment, the specific method for destroying the first weak seal 240 and the second weak seal 242 is not limited to the method of destroying by the pressure of the swallowing auxiliary substance 40.

  The configurations of the first weak seal 240 and the second weak seal 242 are the same as the configurations of the first weak seal 140 to the fourth weak seal 146 according to the first embodiment. The configurations of the bottom strong seal 260 and the side strong seal 262 are the same as those of the bottom strong seal 160 and the side strong seal 162 according to the first embodiment. Therefore, detailed description thereof will not be repeated here.

  In the present embodiment, the two corners of the portion corresponding to the tip of the open space 234 in the container body 220 are bent. However, in FIG. 6, in order to make it easy to grasp the configuration of the pharmaceutical composition container 210, only one of the corners is bent. The reason why the two corners are bent is to make it easier to insert the portion corresponding to the tip of the opening-equipped space 234 into the cover 222 as in the first embodiment. Therefore, if there is no particular problem, only one of the two corners may be bent.

  The manufacturing procedure and usage method of the pharmaceutical composition container 210 according to this embodiment are the same as the manufacturing procedure and usage method of the pharmaceutical composition container 10 according to the first embodiment. Therefore, detailed description thereof will not be repeated here.

  As described above, the pharmaceutical composition container 210 according to this embodiment has the following six effects. The first effect is that the first pharmaceutical composition 80 can be swallowed easily. A 2nd effect is an effect that the bitterness is suppressed when the 1st pharmaceutical composition 80 has a bitter taste. The third effect is that the first pharmaceutical composition 80 can be prevented from scattering in the mouth. The fourth effect is that various types of solids can be taken by persons who have difficulty in swallowing. The fifth effect is an effect that cleanliness when taking the first pharmaceutical composition 80 can be enhanced. Since the reason for achieving these effects is the same as in the first embodiment, detailed description thereof will not be repeated here. The sixth effect is an effect that the residual amount of the pharmaceutical composition 80 inside the pharmaceutical composition container 210 can be reduced (in the case of this embodiment, the residual amount can be made an amount close to zero). .

< Reference form>
Hereinafter, the pharmaceutical composition container 310 according to the reference embodiment of the present invention will be described. In addition, the same code | symbol is attached | subjected to the same thing as what was demonstrated in 1st Embodiment and 2nd Embodiment. In this reference embodiment, detailed description thereof will not be repeated.

Figure 7 is a partially cutaway view of a pharmaceutical composition container 310 to the reference embodiment. The configuration of the pharmaceutical composition container 310 according to the present embodiment will be described with reference to FIG. The pharmaceutical composition container 310 according to this reference embodiment includes a container body 320 and a cover 322. The container body 220 is formed by welding the outer edges of the two laminated materials 50. The cover 222 is separated from the container body 220. In this embodiment, the sheet forming the cover 222 is formed of a known resin.

  The container main body 320 has a bag storage chamber 330, a first pharmaceutical composition chamber 334, a second pharmaceutical composition chamber 336, and an open space 338. The bag storage chamber 330, the first pharmaceutical composition chamber 334, and the second pharmaceutical composition chamber 336 are formed so as to be airtight with respect to the external space around the container body 320.

  An auxiliary substance storage bag 340 is stored in the bag storage chamber 330. The auxiliary substance storage bag 340 is fixed in the bag storage chamber 330 by an outer peripheral strong seal 462 described later.

  The auxiliary substance storage bag 340 stores the swallowing auxiliary substance 40. The strength of one end of the auxiliary substance storage bag 340 facing the first weak seal 440 described later has the same structure as that of the first weak seal 140 to the fourth weak seal 146 according to the first embodiment. . This part can therefore be destroyed by the pressure of the swallowing aid 40. The swallowing auxiliary substance 40 is sterilized together with the auxiliary substance containing bag 340 and then sandwiched between the container main bodies 320. After that, the outer peripheral strong seal 462 is formed, so that the auxiliary substance storage bag 340 is bonded to the outer peripheral strong seal 462.

  In the first pharmaceutical composition chamber 334, the first inclusion 42 is accommodated. A first pharmaceutical composition 80 is stored in the first stored product 42. The powder 344 is accommodated in the second pharmaceutical composition chamber 336. Until the first weak seal 440 to the third weak seal 444 are peeled off, the open space 338 in this embodiment is an empty room.

  The bag storage chamber 330 and the first pharmaceutical composition chamber 334 are partitioned by a first weak seal 440. The first pharmaceutical composition chamber 334 and the second pharmaceutical composition chamber 336 are partitioned by a second weak seal 442. The second pharmaceutical composition chamber 336 and the open space 338 are partitioned by a third weak seal 444. The first weak seal 440, the second weak seal 442, and the third weak seal 444 (collectively referred to as “first weak seal 440 to third weak seal 444”) are the spaces formed by the container body 320. It is arranged in a portion between two adjacent ones.

The strength of the first weak seal 440 to the third weak seal 444 is lower than the strength of the outer peripheral strong seal 462. The outer peripheral strong seal 462 is a portion where the edge of the container body 320 is bonded. In the case of this reference form, the strength of the first weak seal 440 to the third weak seal 444 is a strength that can be broken by the pressure of the swallowing auxiliary substance 40 as in the first embodiment and the second embodiment. As in the first embodiment and the second embodiment, the specific method for breaking the first weak seal 440 to the third weak seal 444 is limited to a method of breaking by the pressure of the swallowing auxiliary substance 40. Not.

  The configurations of the first weak seal 440 to the third weak seal 444 are the same as the configurations of the first weak seal 140 to the fourth weak seal 146 according to the first embodiment. The configuration of the outer peripheral strong seal 462 is the same as that of the side strong seal 162 according to the first embodiment. Therefore, detailed description thereof will not be repeated here.

The manufacturing procedure of the pharmaceutical composition container 310 according to this reference embodiment will be described. The first step is a step in which two laminated materials 50 are overlapped and the outer edges thereof are heated. However, the portion where the auxiliary substance storage bag 340 is sandwiched is not heated. The second step is a step of heating the vicinity of the first weak seal 440 in the laminated material 50. Thereby, the first weak seal 440 is formed. The third step is a step of inserting the first inclusion 42 between the laminated materials 50. The fourth step is a step of heating the area between the first pharmaceutical composition chamber 334 and the second pharmaceutical composition chamber 336 in the laminated material 50. As a result, the second weak seal 442 is formed. The fifth step is a step of filling powder 344 between the laminated materials 50. The sixth step is a step of heating the area between the second pharmaceutical composition chamber 336 and the open space 338 in the laminated material 50. Thereby, the third weak seal 444 is formed. The seventh step is a step of inserting the auxiliary substance storage bag 340 between the laminated materials 50. At this time, first, a portion of the first weak seal 440 in the container body 320 is bent, and the bag storage chamber 330 is directed upward. When the bag storage chamber 330 faces upward, the opening of the bag storage chamber 330 is greatly opened, and the auxiliary substance storage bag 340 is inserted therein. The eighth step is a step of heating a portion of the outer edge of the container body 320 where the auxiliary substance storage bag 340 is sandwiched. The ninth step is a step of covering the cover 322 outside the portion of the container body 320 that forms the open space 338. The pharmaceutical composition container 310 completed through these steps is stored in a paper box (not shown) and distributed.

Methods of using such pharmaceutical composition container 310 to the reference embodiment, except that first remove the cover 322 from the part forming the apertured space 338 of the container main body 320, a pharmaceutical composition according to the first embodiment container 10 It is the same as the usage method of. Therefore, detailed description thereof will not be repeated here.

As described above, the pharmaceutical composition container 310 according to this preferred embodiment achieves five effects described below. The first effect is that the granular drug or other pharmaceutical composition 80 can be swallowed easily. A 2nd effect is an effect that the bitterness is suppressed when the 1st pharmaceutical composition 80 has a bitter taste. The third effect is that there is no need to worry about the stability of the drug. A 4th effect is an effect that the cleanliness at the time of taking the 1st pharmaceutical composition 80 and the powder 344 can be improved. The fifth effect is that the residual amount of the pharmaceutical compositions 80 and 82 inside the pharmaceutical composition container 310 can be reduced (in the case of this embodiment, the residual amount can be made an amount close to zero). It is. Since the reason for achieving these effects is the same as in the first embodiment, detailed description thereof will not be repeated here.

< Third embodiment>
Hereinafter, the pharmaceutical composition container 510 according to the third embodiment of the present invention will be described. In addition, the same code | symbol is attached | subjected to the same thing as what was demonstrated in 1st Embodiment and 2nd Embodiment. In the present embodiment, detailed description thereof will not be repeated.

  FIG. 8 is a partially cutaway view of the pharmaceutical composition container 510 according to the present embodiment. The configuration of the pharmaceutical composition container 510 according to this embodiment will be described with reference to FIG. A pharmaceutical composition container 510 according to this embodiment includes a container body 520 and a cover 522 integrated with the container body 520. Similar to the second embodiment, the container main body 520 and the cover 522 according to the present embodiment are formed by folding one laminated material 50 in two and bonding the outer circumferences together. In FIG. 8, the hatching at the right end of the pharmaceutical composition container 510 indicates a cross section of the laminated material 50.

  The container body 520 includes a swallowing auxiliary substance chamber 530, an intermediate chamber 532, a first pharmaceutical composition chamber 534, a second pharmaceutical composition chamber 536, and an open space 538. The swallowing auxiliary substance chamber 530, the intermediate chamber 532, the first pharmaceutical composition chamber 534, and the second pharmaceutical composition chamber 536 are formed so as to be airtight with respect to the external space around the pharmaceutical composition container 510. Yes. The cover 522 can cover the outside of the portion of the container body 520 that forms the open space 538.

  A third pharmaceutical composition 84 is accommodated in the first pharmaceutical composition chamber 534. The third pharmaceutical composition 84 is a powder medicine. A fourth pharmaceutical composition 86 is accommodated in the second pharmaceutical composition chamber 536. The fourth pharmaceutical composition 86 is a different type of powder from the third pharmaceutical composition 84. Of course, it goes without saying that granular medicines and other substances may be accommodated in the first pharmaceutical composition chamber 534 and the second pharmaceutical composition chamber 536.

  In the swallowing auxiliary substance chamber 530, the first pharmaceutical composition room 534, and the second pharmaceutical composition room 536, a gas that does not affect the third pharmaceutical composition 84, the fourth pharmaceutical composition 86, and the swallowing auxiliary substance 40 is present. Enclosed as necessary.

  Until the first weak seal 640 to the fourth weak seal 646 are peeled off, the intermediate chamber 532 and the open space 538 are empty. The open space 538 has an opening.

  The swallowing auxiliary substance chamber 530 and the intermediate chamber 532 are partitioned by a first weak seal 640. The intermediate chamber 532 and the first pharmaceutical composition chamber 534 are partitioned by a second weak seal 642. The first pharmaceutical composition chamber 534 and the second pharmaceutical composition chamber 536 are partitioned by a third weak seal 644. A space between the second pharmaceutical composition chamber 536 and the open space 538 is partitioned by a fourth weak seal 646.

  The strength of the first weak seal 640 to the fourth weak seal 646 is lower than the strength of the bottom strong seal 660 and the strength of the side strong seal 662. In the case of the present embodiment, the strength of the first weak seal 640 to the fourth weak seal 646 is the pressure of the swallowing auxiliary substance 40 (this pressure is due to the fact that an adult applied force from the outside of the swallowing auxiliary substance chamber 30). ) That can be destroyed by In addition, between the swallowing auxiliary substance chamber 530 and the intermediate chamber 532, between the intermediate chamber 532 and the first pharmaceutical composition chamber 534, between the first pharmaceutical composition chamber 534 and the second pharmaceutical composition chamber 536, and The specific method for breaking the space between the second pharmaceutical composition chamber 536 and the open space 538 is not limited to the method of breaking by the pressure of the swallowing auxiliary substance 40.

  The method of using the pharmaceutical composition container 510 according to the present embodiment is the same as the method of using the pharmaceutical composition container 10 according to the first embodiment. Therefore, detailed description thereof will not be repeated here.

  As described above, the pharmaceutical composition container 510 according to the present embodiment has the following four effects. A 1st effect is an effect that a powder medicine and other pharmaceutical compositions can be swallowed easily. The second effect is that there is no need to worry about the stability of the drug. The third effect is that the pharmaceutical composition container 510 according to the present embodiment is used to swallow the pharmaceutical composition by providing a step at a portion adjacent to the third weak seal 644 in the side strong seal 662. This is an effect of preventing the tip of the pharmaceutical composition container 510 from entering the mouth of the patient 200 too much. A 4th effect is an effect that the cleanliness at the time of taking the 3rd pharmaceutical composition 84 and the 4th pharmaceutical composition 86 can be improved.

< Fourth embodiment>
Hereinafter, the pharmaceutical composition container 710 according to the fourth embodiment of the present invention will be described. In addition, the same code | symbol is attached | subjected to the same thing as what was demonstrated in 1st Embodiment thru | or 3rd Embodiment and an embodiment with invention different from this invention . In the present embodiment, detailed description thereof will not be repeated.

  FIG. 9 is a partially cutaway view of the pharmaceutical composition container 710 according to the present embodiment. A pharmaceutical composition container 710 according to this embodiment includes a container body 820 and a cover 822 integrated with the container body 820. The pharmaceutical composition container 710 is formed by bonding two laminated materials 50 as in the first embodiment and the third embodiment.

  The container body 820 includes a swallowing auxiliary substance chamber 830, a first pharmaceutical composition chamber 834, and a space 838 with an opening. The swallowing auxiliary substance chamber 830 and the first pharmaceutical composition chamber 834 are formed so as to be airtight with respect to the external space around the pharmaceutical composition container 710.

  The third pharmaceutical composition 84 is accommodated in the first pharmaceutical composition chamber 834. Needless to say, the first pharmaceutical composition chamber 834 may contain a granular drug or other substance.

  In the swallowing auxiliary substance chamber 830 and the first pharmaceutical composition room 834, a gas that does not affect the third pharmaceutical composition 84 and the swallowing auxiliary substance 40 is sealed as necessary.

  Until the first weak seal 840 and the second weak seal 842 are peeled, the open space 838 is an empty space. The space 838 with an opening has an opening.

  The swallowing auxiliary substance chamber 830 and the first pharmaceutical composition chamber 834 are partitioned by a first weak seal 840. The first pharmaceutical composition chamber 834 and the open space 838 are partitioned by a second weak seal 842.

  The strength of the first weak seal 840 and the second weak seal 842 is lower than the strength of the bottom strong seal 860 and the strength of the side strong seal 862.

  The usage method of the pharmaceutical composition container 710 according to the present embodiment is the same as the usage method of the pharmaceutical composition container 10 according to the first embodiment. Therefore, detailed description thereof will not be repeated here.

  As described above, the pharmaceutical composition container 710 according to this embodiment has the following three effects. A 1st effect is an effect that a powder medicine and other pharmaceutical compositions can be swallowed easily. The second effect is that there is no need to worry about the stability of the drug. A 3rd effect is an effect that the cleanliness at the time of taking the 3rd pharmaceutical composition 84 can be improved.

< Fifth embodiment>
The fifth embodiment of the present invention will be described below. In addition, the same code | symbol is attached | subjected to the same thing as what was demonstrated in 1st Embodiment. In the present embodiment, detailed description thereof will not be repeated.

<Description of structure>
FIG. 10 is a partially cutaway view of the pharmaceutical composition container 260 according to the present embodiment. The pharmaceutical composition container 260 according to the present embodiment is a single synthetic resin (low-density polyethylene, PET (polyethylene terephthalate), a soft resin that can be bent such as a composite resin thereof, and capable of heat sealing). It is formed by folding the manufactured sheet in half, pasting the ends of the half-folded sheet together, cutting out the pasted portion, and adjusting the outer shape.

  A portion where the ends of the sheet are bonded together is a side strong seal 270. A plurality of spaces are provided inside the pharmaceutical composition container 260. A space between the plurality of spaces is closed by a first weak seal 300, a second weak seal 302, and a third weak seal 304. The first weak seal 300 has a first area 311, an intermediate chamber 312, and a second area 314.

  One of the spaces inside the pharmaceutical composition container 260 is a swallowing auxiliary substance chamber 280. In the swallowing auxiliary substance chamber 280, the swallowing auxiliary substance 40 is accommodated. When force is applied to the swallowing aid substance 40 from the outside of the pharmaceutical composition container 260, the first area 311 of the first weak seal 300 is easily opened by the pressure received from the swallowing aid substance 40. When the first area 311 is opened, the swallowing auxiliary substance 40 is pushed into the intermediate chamber 312. Thereafter, similarly, the second area 314, the second weak seal 302, and the third weak seal 304 are sequentially opened. This can be realized because the strength of the first weak seal 300, the second weak seal 302, and the third weak seal 304 is lower than that of the side strong seal 270.

  One type of space inside the pharmaceutical composition container 260 includes a first pharmaceutical composition chamber 282 and a second pharmaceutical composition chamber 284. In these, the first storage item 212 or the second storage item 213 is accommodated. The types of the pharmaceutical composition stored in the first storage 212 stored in the first pharmaceutical composition chamber 282 and the pharmaceutical composition stored in the second storage 213 stored in the second pharmaceutical composition chamber 284 Is different.

  There is also an open space 286 in one of the spaces inside the pharmaceutical composition container 260. A space 286 with an opening is provided at one end of the pharmaceutical composition container 260, and a chute for taking the first collection 212 or the second collection 213 (that is, the first collection 212 or the second collection 213 is taken by the patient). Device for sliding down into the mouth).

  Of the both ends of the pharmaceutical composition container 260, one end on the side opposite to the side where the open space 286 is provided is a cover 288. The boundary between the swallowing auxiliary substance chamber 280 and the cover 288 is a bottom strong seal 272. Since the strength of the bottom strong seal 272 is the same as that of the side strong seal 270, even if a force is applied to the swallowing auxiliary substance 40 from the outside of the pharmaceutical composition container 260, it does not peel off. In the description of the pharmaceutical composition container 260 according to the present embodiment, a portion closer to the second pharmaceutical composition chamber 284 than the cover 288 is referred to as a “container body”.

  FIG. 11 is a schematic view of a portion corresponding to the back surface of the pharmaceutical composition container 260 according to the present embodiment when viewed from the surface shown in FIG. 10. As is clear from FIG. 11, a label 262 is attached to the pharmaceutical composition container 260 according to the present embodiment.

<Features unique to this embodiment>
A characteristic of the pharmaceutical composition container 260 according to this embodiment when compared with the pharmaceutical composition container according to another embodiment is that a cover 288 is provided at one end and the other end is inserted into the cover 288. cover insert 321 is provided that, part of the width of the pharmaceutical composition container 260 is wider at the base 331 of the portion to be inserted into the cover 2 8 8, the bottom strong seal 272 second weak seal 302 The third weak seal 304 is bent and the tip of the cover insertion portion 321 is inserted into the cover 288, and the root 331 is outside the cover 288. 12, the cover insert 321 in the cover 2 8 8 is inserted, and shows a situation where the base 331 is out of the cover 2 8 8. As can be seen from FIG. 12, the base 331 is recessed, and the cover insertion portion 321 can be easily pulled out by inserting a finger there. Note that FIG. 13 is a diagram of a portion corresponding to the rear surface when viewed from the surface illustrated in FIG. 12 in the situation illustrated in FIG. The label 262 occupies most of the back surface of the pharmaceutical composition container 260.

<Usage>
When using the pharmaceutical composition container 260 according to the present embodiment, Put your finger on the base 331 as described above, pulling out the cover insert 321 described above as it is from the cover 2 8 8. When the cover insertion portion 321 is pulled out, the cover insertion portion 321 is put into the patient's mouth. Subsequent usage is the same as in other embodiments and modifications thereof.

<Description of effects>
Since the pharmaceutical composition container 260 according to the present embodiment can put a finger on the base 331 of the cover insertion portion 321, the cover insertion portion 321 can be easily pulled out.

  Moreover, the pharmaceutical composition container 260 according to this embodiment has the same effects as those of the first embodiment.

< Sixth embodiment>
The sixth embodiment of the present invention will be described below. In addition, the same code | symbol is attached | subjected to the same thing as what was demonstrated in 1st Embodiment. In the present embodiment, detailed description thereof will not be repeated.

<Description of structure>
FIG. 14 is a partially cutaway view of the pharmaceutical composition container 400 according to this embodiment. Similar to the sixth embodiment, the pharmaceutical composition container 400 according to the present embodiment was obtained by folding one synthetic resin sheet in two and bonding the ends of the two folded sheets together. It is formed by cutting out the part and adjusting the outer shape.

  A portion where the ends of the sheet are bonded together is the side strong seal 410. A plurality of spaces are provided inside the pharmaceutical composition container 400. The plurality of spaces are closed with a first weak seal 441, a second weak seal 443, and a third weak seal 445. The first weak seal 441 has a first area 450, an intermediate chamber 452, and a second area 454.

One of those spaces is a swallowing auxiliary substance chamber 420. In the swallowing auxiliary substance chamber 420, the swallowing auxiliary substance 40 is accommodated. Applying pressure to swallowing auxiliary substances 40 from the outside of the pharmaceutical composition container 400, the first zone 450 and the second zone 454, a first weak seal 300 in the fifth embodiment, the second weak seal 302 and, It opens sequentially like the 3rd weak seal 304. The reason for such opening is the same as in the fifth embodiment.

  One type of space inside the pharmaceutical composition container 400 includes a first pharmaceutical composition chamber 422 and a second pharmaceutical composition chamber 424. In these, the first storage item 212 or the second storage item 213 is accommodated. What is the pharmaceutical composition stored in the first stored product 212 stored in the first pharmaceutical composition chamber 422 and what is stored in the second stored product 213 stored in the second pharmaceutical composition chamber 424? Is different.

One of those spaces is also an open space 426. The space 426 with an opening becomes a chute for taking the first storage item 212 and the second storage item 213, similarly to the space 286 with an opening of the fifth embodiment.

Of the both ends of the pharmaceutical composition container 400, one end opposite to the side where the open space 426 is provided is a cover 428. Boundary between swallowing auxiliary substance chamber 420 and the cover 4 2 8 has a bottom strong seal 412. Since the strength of the bottom strong seal 412 is the same as that of the side strong seal 410, even if a force is applied to the swallowing auxiliary substance 40 from the outside of the pharmaceutical composition container 400, it does not peel.

<Features unique to this embodiment>
Pharmaceutical composition container 400 unique features according to the present embodiment, the cover 4 2 8 is provided at one end, the bottom strong seal 412 and the apertured space when compared to such pharmaceutical composition container to another embodiment 426 is bent and the base portion is provided, a portion apertured space 426 is provided is inserted into the cover 4 2 in 8, the distal end 480 of the portion apertured space 426 is provided with rounded and it has, and is that part of the edge 482 of the cover 4 2 8 is cut away. In the description of the pharmaceutical composition container 400 of this embodiment, than the cover 4 2 8 part of the second pharmaceutical composition chamber 424 side is referred to as a "container body".

<Usage>
When using the pharmaceutical composition container 400 of this embodiment, the pulled towards the apertured space 426 of both ends of the pharmaceutical composition container 400 is provided from the cover 4 2 8. Subsequent usage is the same as in the other embodiments.

<Description of effects>
Pharmaceutical composition container 400 according to this embodiment, during manufacture, a notched edge 482 of the part and the cover 4 2 8 apertured space 426 is provided is bent so as to face each other. FIG. 15 shows the situation where the pharmaceutical composition container 400 is folded during manufacture. After pharmaceutical composition container 400 is folded, a portion apertured space 426 is provided is inserted into the cover 4 2 8. In this case, open mouth of the cover 4 2 8 caught on any portion of the rim 482 the tip 480 of the portion apertured space 426 is provided is notched in the cover 4 2 8. Since the mouth of the cover 4 2 8 is opened, the tip 480 enters the cover 4 2 8 smoothly. Figure 16 illustrates a pharmaceutical composition container 400 after the portion of the apertured space 426 is provided is inserted into the cover 4 2 8.

  Moreover, the pharmaceutical composition container 400 according to the present embodiment has the same effects as those of the first embodiment.

< Seventh embodiment>
The seventh embodiment of the present invention will be described below. In addition, the same code | symbol is attached | subjected to the same thing as what was demonstrated in 1st Embodiment. In the present embodiment, detailed description thereof will not be repeated.

<Description of structure>
FIG. 17 is a partially cutaway view of a pharmaceutical composition container 500 according to this embodiment. Similarly to the fifth embodiment, the pharmaceutical composition container 500 according to the present embodiment was obtained by folding a sheet of synthetic resin into two and bonding the ends of the folded sheet to each other. It is formed by cutting out the part and adjusting the outer shape.

  A portion where the ends of the sheet are bonded together is a side strong seal 511. A plurality of spaces are provided inside the pharmaceutical composition container 500. The plurality of spaces are closed with a first weak seal 540, a second weak seal 542, and a third weak seal 544. The first weak seal 540 has a first area 550, an intermediate chamber 552, and a second area 554.

One of the spaces inside the pharmaceutical composition container 500 is a swallowing auxiliary substance chamber 521. The swallowing auxiliary substance 40 is accommodated in the swallowing auxiliary substance chamber 521. Applying pressure to swallowing auxiliary substances 40 from the outside of the pharmaceutical composition container 500, the first zone 550 and the second zone 554, a first weak seal 300 in the fifth embodiment, the second weak seal 302 and, It opens sequentially like the 3rd weak seal 304. The reason for such opening is the same as in the fifth embodiment.

  One type of space inside the pharmaceutical composition container 500 includes a first pharmaceutical composition chamber 523 and a second pharmaceutical composition chamber 524. In these, the first storage item 212 or the second storage item 213 is accommodated. What is the pharmaceutical composition stored in the first stored product 212 stored in the first pharmaceutical composition chamber 523 and what is stored in the second stored product 213 stored in the second pharmaceutical composition chamber 524? Is different.

One of those spaces also has an open space 526. The space 526 with an opening becomes a chute for taking the first storage item 212 and the second storage item 213, similarly to the space 286 with an opening according to the fifth embodiment.

  Of the both ends of the pharmaceutical composition container 500, one end on the opposite side to the side where the open space 526 is provided is a cover 528. A boundary between the swallowing auxiliary substance chamber 521 and the cover 528 is a strong bottom seal 512. Since the strength of the bottom strong seal 512 is the same as that of the side strong seal 511, even if a force is applied to the swallowing auxiliary substance 40 from the outside of the pharmaceutical composition container 500, it does not peel off. In the description of the pharmaceutical composition container 500 according to the present embodiment, a portion closer to the second pharmaceutical composition chamber 524 than the cover 528 is referred to as a “container body”.

<Features unique to this embodiment>
FIG. 18 is a partially cutaway view showing one end of the pharmaceutical composition container 500 being manufactured. FIG. 19 is a perspective view showing one end of the pharmaceutical composition container 500 being manufactured. With reference to FIG. 18 and FIG. 19, the unique features of the pharmaceutical composition container 500 according to the present embodiment when compared with the pharmaceutical composition container according to another embodiment will be described. The feature is that the bottom strong seal 512 and the base of the part where the opening space 526 is provided are bent, the part where the opening space 526 is provided is inserted into the cover 528, and the side strong seal 511 Among them, a welding margin 514 is provided at the tip portion 516 inserted into the cover 528. The welding margin 514 is folded back as shown in FIG. 19 and welded to the tip portion 516.

<Usage>
The method of using the pharmaceutical composition container 500 according to this embodiment is the same as that in the sixth embodiment.

<Description of effects>
Since the pharmaceutical composition container 500 according to the present embodiment has the above-described structure, even if burrs are generated at the end of the side strong seal 511, the burrs are unlikely to contact the patient's mouth. Because burr is difficult to touch, it is hard to hurt patient's mouth.

  Moreover, the pharmaceutical composition container 500 according to the present embodiment has the same effects as those of the first embodiment.

< Eighth embodiment>
The eighth embodiment of the present invention will be described below. In addition, the same code | symbol is attached | subjected to the same thing as what was demonstrated in 1st Embodiment. In the present embodiment, detailed description thereof will not be repeated.

<Description of structure>
FIG. 20 is a partially cutaway view of the pharmaceutical composition container 351 according to the present embodiment. Similar to the fifth embodiment, the pharmaceutical composition container 351 according to the present embodiment is obtained by folding one synthetic resin sheet in two and bonding the ends of the folded sheet to each other. It is formed by cutting out the part and adjusting the outer shape.

  A portion where the ends of the sheet are bonded together is a side strong seal 361. A plurality of spaces are provided inside the pharmaceutical composition container 351. The plurality of spaces are closed with a first weak seal 390, a second weak seal 392, and an opening formation scheduled portion 394. The first weak seal 390 has a first area 401, an intermediate chamber 403, and a second area 405.

One of the spaces inside the pharmaceutical composition container 351 is a swallowing auxiliary substance chamber 370. The swallowing auxiliary substance 40 is accommodated in the swallowing auxiliary substance chamber 370. When a force is applied to the swallowing aid substance 40 from the outside of the pharmaceutical composition container 351, the first area 401 and the second area 405 correspond to the first weak seal 300, the second weak seal 302, and the sixth embodiment, and It opens sequentially like the 3rd weak seal 304. The reason for such opening is the same as in the fifth embodiment.

  One type of space inside the pharmaceutical composition container 351 includes a first pharmaceutical composition chamber 372 and a second pharmaceutical composition chamber 374. A first stored product 212 is accommodated in the first pharmaceutical composition chamber 372. A well-known tablet 352 is accommodated in the second pharmaceutical composition chamber 374.

  Of the both ends of the pharmaceutical composition container 351, one end on the side opposite to the side where the opening formation scheduled portion 394 is provided is a cover 378. The boundary between the swallowing auxiliary substance chamber 370 and the cover 378 is a bottom strong seal 362. Since the strength of the bottom strong seal 362 is the same as that of the side strong seal 361, even if a force is applied to the swallowing auxiliary substance 40 from the outside of the pharmaceutical composition container 351, it does not peel off. In the description of the pharmaceutical composition container 351 according to the present embodiment, a portion closer to the second pharmaceutical composition chamber 374 than the cover 378 is referred to as a “container body”.

  When the pharmaceutical composition container 351 according to the present embodiment is completed, a portion where the opening formation scheduled portion 394 is provided is inserted into the cover 378 so as to be removable. FIG. 21 is an external view of the pharmaceutical composition container 351 at this time.

<Features unique to this embodiment>
The unique characteristic of the pharmaceutical composition container 351 according to this embodiment when compared with the pharmaceutical composition container according to another embodiment is that an opening formation scheduled portion 394 is provided in a portion 354 inserted into the cover 378, In addition, the seal strength of the opening formation scheduled portion 394 is weaker than the seal strength of the side strong seal 361.

<Usage>
The usage method of the pharmaceutical composition container 351 according to this embodiment is the same as that of the sixth embodiment.

<Description of effects>
In the pharmaceutical composition container 351 according to this embodiment, the seal strength of the opening formation scheduled portion 394 is weaker than the seal strength of the side strong seal 361. Therefore, when the portion 354 provided with the opening formation scheduled portion 394 is put into the patient's mouth and the pharmaceutical composition container 351 is squeezed, the opening formation scheduled portion 394 opens in the mouth. Thereby, an opening is formed. The opening allows communication between the outside of the pharmaceutical composition container 351 and the space. As a result, it is possible to put the first storage item 212 and the tablet 352 into the patient's mouth without touching the part originally inserted in the cover 378.

  Moreover, the pharmaceutical composition container 351 according to this embodiment has the same effects as those of the first embodiment.

<Description of modification>
The above-described pharmaceutical composition containers 10 , 210 , 260 , 351 , 400 , 500 , 510 , 710 are illustrated to embody the technical idea of the present invention. This does not limit the material of the container main bodies 20 and 220 to the above-described embodiment. This does not limit the shape of the container main body 20 , 220 , 520 , 720, the shape of each space, the shape of the opening, their dimensions, their structure, their arrangement, and the like to the above-described embodiments. The pharmaceutical composition container 10 , 210 , 260 , 351 , 400 , 500 , 510 , 710 described in the present embodiment can be variously modified within the scope of the technical idea of the present invention.

  For example, the form of the 1st thing 42 or the 2nd thing 44 is not limited to what was mentioned above. For example, the outer shape may be a rectangle. Moreover, it replaces with the 1st thing 42 and the 2nd thing 44, and the well-known capsule may be accommodated.

The container body 20, 22 0, the shape of the space having the 520,720 is not particularly limited. For example, the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36 shown in FIG. 1 have a hexagonal shape, which may be a triangle, a rectangle, a pentagon, or a heptagon or more polygon. It may be circular or elliptical. Further, the number of spaces the container body 20, 22 0 has may be in four or more.

Further, the pharmaceutical composition container 210 according to the second embodiment and the pharmaceutical composition container 710 according to the fourth embodiment may be provided with the same empty space as the intermediate chamber 32 according to the first embodiment. Furthermore, in the first embodiment, the intermediate chamber 32 is not an essential space.

The container body 2 0 according to the first embodiment is not limited to two sheets to those bonded to each other. The container main body 220 according to the second embodiment is not limited to one in which the outer edges of one sheet are bonded together. The container body 220 according to the second embodiment may be a laminate of two sheets. Container body 2 0 according to the first embodiment may be formed by bonding the outer edge to the single sheet folded in two.

  In the above embodiment, the case where the pharmaceutical composition is a powder or granule and the swallowing auxiliary substance is jelly has been described, but the pharmaceutical composition and the swallowing auxiliary substance applied to the present invention are not limited thereto. Needless to say. For example, the pharmaceutical composition may be a tablet, capsule or simple mass in addition to powder or granule. The pharmaceutical composition may not be accommodated in the first pharmaceutical composition chamber 34 or the second pharmaceutical composition chamber 36 in the form of a inclusion. That is, the pharmaceutical composition does not have to be wrapped by wafers or other packaging materials. Furthermore, the thing shape | molded as a pharmaceutical composition is not limited to the thing normally handled as a pharmaceutical. For example, the product molded as a pharmaceutical composition may be a food that has been recognized to improve health. The swallowing aid may be honey, custard cream, peanut spread, cheese spread, etc. in addition to an aqueous solution. However, it is preferable that the swallowing assisting substance has a fluidity that can be moved back and forth in the space provided in the container body in an environment where the pharmaceutical composition container is used.

  Incidentally, the compounding agent may be accommodated in one pharmaceutical composition chamber as long as it has been confirmed that the drug does not change while the drug is distributed or stored. The compounding agent described here means a mixture.

  When the inclusion is stored in the pharmaceutical composition container, the inclusion is made of various materials that have been conventionally used as an edible film material in addition to the above-described starch-oblate having a thickness of 15 μm. Can be used. These materials include polysaccharides (eg, pullulan, arabinoxylan, guar gum degradation products, sodium alginate, carrageenan, agar, pectin, cellulose, etc.) and peptide substances (eg, gelatin, silk protein degradation products, casein) Decomposition products). These materials can be used alone or in combination of two or more.

  The pharmaceutical composition container according to the present invention can be suitably used as a container for taking medicine. In particular, the container for taking medicine can be suitably used for a medicine filled by the system described below. The system is a system in which a plurality of auger filling machines are installed, a transport system and a weighing system are added, connected to a pharmaceutical production line, and automatic operation is performed for a long time.

10 , 210 , 260 , 310 , 351 , 400 , 500 , 510, 710 Pharmaceutical composition container 20, 220, 320, 520, 720, 820 Container body 22 , 22 2, 288, 378, 428, 322 , 522 , 528 , 822 Cover 30, 230, 370, 420, 530, 830 Swallowing auxiliary substance chamber 32, 532 Intermediate chamber 34, 282, 334, 372, 422, 523, 534, 834 First pharmaceutical composition chamber 36, 284, 336 374, 424, 524, 536 Second pharmaceutical composition chamber 38, 234, 286, 338, 426, 526, 538, 838 Open space 40 Swallowing assisting substance 42, 212 First inclusion 44, 213 Second inclusion 50 Laminate 60 Opening 80 First pharmaceutical composition 82 Second pharmaceutical composition 84 Third pharmaceutical composition 86 Fourth pharmaceutical composition 1 0 Outer material 102 Intermediate material 104 Closure material 140, 240, 300, 390, 440, 441, 540, 640, 840 First weak seal 142, 242, 302, 392, 442, 443, 542, 642, 842 Second weak Seals 144, 304, 444, 445, 544 Third weak seal 146 Fourth weak seal 160, 260, 272, 362, 412, 512, 660, 860 Bottom strong seal 162, 262, 270, 361, 410, 511, 662 , 862 Side strong seal 200 Patient 230, 280, 521 Swallowing auxiliary substance room 232 Pharmaceutical composition room 262 Label 311, 401, 450, 550 First area 312, 403, 452, 552 Intermediate room 314, 405, 454, 554 Second area 321 Cover insertion part 330 Bag housing chamber 331 Root 340 Auxiliary substances bag 344 powdered medicine 352 tablets 394 opening forming scheduled portion 462 outer peripheral strong seal 480 tip 482 end 516 distal portion

Claims (3)

A pharmaceutical composition container comprising at least three spaces in the container body,
The pharmaceutical composition container further comprises a cover;
The space between two adjacent spaces is closed,
The space between the two adjacent spaces opens when a force is applied from the outside of the pharmaceutical composition container,
At least one of the spaces is a space with an opening having an opening,
A swallowing aid substance is housed in a swallowing aid substance chamber that is at least one of the spaces,
A pharmaceutical composition is housed in a pharmaceutical composition chamber which is at least one of the spaces;
A part of the container body that forms the space with the opening is covered by the cover ,
The cover is integral with the container body;
The at least three spaces and the cover are arranged to form one row;
The open space is located at one end of the row;
The cover is disposed at the other end of the row;
The container body and the cover are foldable, and the container body and the cover are bent, so that the opening and the cover are opposed to each other. container. A containment is accommodated in the pharmaceutical composition chamber,
At least the surface of the inclusion is dissolved in the swallowing aid component;
The pharmaceutical composition container according to claim 1, wherein the pharmaceutical composition is contained in the inclusion. A pharmaceutical composition container comprising a plurality of spaces in the container body,
The container body is provided with an opening formation scheduled portion where the opening is scheduled to be formed,
When the force is applied from the outside of the pharmaceutical composition container, the opening opens the opening formation scheduled portion, thereby communicating the outside of the pharmaceutical composition container and the space;
The space between two adjacent spaces is closed,
The space between the two adjacent spaces opens when a force is applied from the outside of the pharmaceutical composition container,
A swallowing aid substance is housed in a swallowing aid substance chamber that is at least one of the spaces,
A pharmaceutical composition is housed in a pharmaceutical composition chamber which is at least one of the spaces;
The container body is bendable;
The pharmaceutical composition container is disposed adjacent to the container main body, is integral with the container main body, and a portion of the container main body where the opening formation scheduled portion is provided is removable. A cover,
The plurality of spaces and the cover are arranged so as to form one row,
The portion of the container body where the opening formation scheduled portion is provided is disposed at one end of the row,
The cover is disposed at the other end of the row;
The cover is bendable;
The pharmaceutical composition container, wherein the container main body and the cover are bent so that a portion where the opening formation scheduled portion is provided is covered by the cover.

Images